Back

ESGO 2023 - 24th European Gynaecological Oncology Congress of the European Society of Gynaecological Oncology

Sep 28 - Oct 01, 2023 | IstanbulTurkey

LARVOL is not affiliated with 24th European Gynaecological Oncology Congress of the European Society of Gynaecological Oncology and all trademarks, logos, and brand names are property of their respective owners

Showing 29 abstracts linked to Trials

Pembrolizumab + Chemotherapy For First-Line Treatment Of Patients With Persistent, Recurrent, Or Metastatic Cervical Cancer: Bevacizumab Subgroup Analysis Based On Protocol-Specified Final Overall Survival Results Of KEYNOTE-826

  • Oral

Magnetic Resonance Imaging Or Expert Ultrasound In Preoperative Local Staging Of Patients With Early-Stage Cervical Cancer: Final Results Of The SENTIX Prospective, Single-Arm, International Trial (CEEGOG CX-01; ENGOT-CX2)

  • Oral

Long-Term Follow Up Of Selinexor Maintenance For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: A Pre-Specified Subgroup Analysis From The Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

  • Oral

Quality-Adjusted Time Without Symptoms Of Disease Or Toxicity In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel In The ENGOT-EN6/GOG-3031/RUBY Trial

  • Oral

DB-1303, A HER2-Targeting ADC, For Patients With Advanced/Metastatic Endometrial Cancer: Preliminary Clinical Results From An Ongoing Phase 1/2a Trial (NCT05150691)

  • Oral

Safety Of Dostarlimab In Combination With Chemotherapy In Patients With Primary Advanced Or Recurrent Endometrial Cancer In A Phase 3, Randomized, Placebo-Controlled Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

  • Oral

Near-Infrared FluORescencE Assessment Of Myocutnaeous Flap Microperfusion For Gynecologic RecONstrucTion (FOREFRONT): A Prospective, Non-Randomized Trial (NCT05071976)

Initial Efficacy And Safety Results From ENGOT-Ov60/GOG-3052/RAMP 201: A Phase 2 Study Of Avutometinib (VS-6766) ± Defactinib In Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

  • Oral

Efficacy Of Subsequent Chemotherapy Followed By PARP Inhibitor Maintenance In Patients With Advanced Ovarian Cancer In The Phase III PAOLA-1/ENGOT-Ov25 Trial

  • Oral

First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)

  • Oral

Niraparib Maintenance Therapy In Patients Aged 75 Years And Older With Platinum-Sensitive Recurrent Ovarian Cancer: A Subgroup Assessment Of The GEICO-88R Study

  • Oral

Results From A Phase I/II Trial Of Tinostamustine Monotherapy In Advanced Solid Tumours (NCT03345485): Safety And Efficacy In A Subset Of Patients With Advanced Ovarian Cancer (OvCa)

  • Poster

PARP-Inhibitors Can Be Applied Together With Tumor Treating Fields (TTFields) To Prolong Survival In An Ovarian Cancer Mouse Model

  • Poster

Hyperthermic Intraperitoneal Chemotherapy In Platinum-Sensitive Relapsed Epithelial Ovarian Cancer: The CHIPOR Randomised Phase III Trial.

  • Oral

Real-World Treatment, Clinical And Patient-Reported Outcomes In Patients With Newly Diagnosed Advanced Ovarian Cancer: Up-Date On The Cumulative Numbers Of Patients Treated At The Sites (NOGGO Ov54, NCT04830709)

  • E-Poster